Pfizer may have to sell parts of its animal health business
This article was originally published in Scrip
Executive Summary
Pfizer may be forced to sell some of its animal health business to obtain antitrust approval for its $68 billion acquisition of Wyeth because of overlaps between their animal health businesses.